A Randomized, Open-Label, Single-Dose, Parallel-Group Study to Evaluate the Relative Bioavailability of LY03010 versus Xeplion® after Intramuscular Injection in Healthy Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502179-48-00

Acronym

LY03010/CT-EUR-101

Enrollment

170

Registered

2023-02-20

Start date

2023-02-23

Completion date

2024-02-12

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

None listed

Sex/Gender

All

Age

18 Years to 64 Years

Portugal

None listed

Source: EU CTIS · Data processed: Feb 4, 2026